Essential tremor

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Freitag, April 12, 2024
American Academy, Efficacy, Safety, Clinical trial, Essential tremor, Abstract, CNS, Propranolol, Tremor, Patient, AAN, Concomitant, Central nervous system, Annual general meeting, Pharmaceutical industry

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showcasing progress of its clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place in Denver, Colorado, April 13 – 18, 2024.

Key Points: 
  • BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showcasing progress of its clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place in Denver, Colorado, April 13 – 18, 2024.
  • “With Essential3, we’ve developed a decentralized trial program unlike any other in ET, and among the first in the industry,” said Marcio Souza, president and chief executive officer of Praxis.
  • “The experiences of patients with ET are often overlooked so we designed a trial that removes typical obstacles to participation and concentrates on endpoints that truly matter.
  • In our earlier Phase 2 Essential1 study, we observed that patients who were already on propranolol experienced additional benefits when adding ulixacaltamide.

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Donnerstag, April 25, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, FDA, Research, Webcast, Prescription, ODD, NEST, European Medicines Agency, Deficit spending, PAM, MCI, Innovation, Hearing, Woman, PBM, Cognition, CIV, MHRA, Therapy, Plasma, Tremor, Safety, Insurance, Natural history, HD, Incidence, EMA, Government, Sale, Essential tremor, PPD, NMDA, Health care, GABAA, Patient, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.
  • In the first quarter of 2024, OBGYNs accounted for the largest share of prescriptions, followed by psychiatrists and PCPs.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $6.2 million in the first quarter of 2024, the first full quarter of sales.
  • ET to review its first quarter 2024 financial results and discuss recent corporate updates.

INSIGHTEC ANNOUNCES EXABLATE PRIME AVAILABILITY IN EUROPE -THE NEXT GENERATION OF MR-GUIDED FOCUSED ULTRASOUND

Retrieved on: 
Dienstag, April 16, 2024
Sale, Parkinson's disease, SDR, Essential tremor, Safety, Intuition, Research, 3D, Acquisition, Neurosurgery, Physician, DSM-IV codes, AC, Health, Feedback, Temperature, Algorithm, CE

HAIFA, Israel and MUNICH, April 16, 2024 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced the CE approval and European launch of Exablate Prime, a significant enhancement to the Exablate Neuro platform. Based on customer input and feedback, Exablate Prime is the culmination of over 10 years of significant research and development designed to increase precision, efficiency, and experience of the surgeon – and the patient.

Key Points: 
  • Like its predecessor, Exablate Prime enables incisionless neurosurgery as an outpatient procedure to provide relief to people living with movement disorders, such as essential tremor and Parkinson's disease.
  • "Our unwavering commitment to enhancing patient care through innovative technology led us to develop Exablate Prime," said Maurice R. Ferre, M.D.
  • "Although Exablate Neuro has revolutionized the field of neurosurgery, Exablate Prime takes it to entirely new levels, pushing the boundaries of what is possible.
  • "With the growing number of European countries supporting focused ultrasound as viable treatment option for essential tremor, Exablate Prime is truly exciting," commented Giuseppe Carbone, vice president of Insightec Europe.

Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use

Retrieved on: 
Mittwoch, April 3, 2024
Epilepsy, CCPS, Health, TLRY, HIV, Arthritis, Post-traumatic stress disorder, Patient, Tilray, Anxiety, Tobacco, Chronic pain, CBD, Essential tremor, Cannabis, TSX, Signs and symptoms, Pain, THC, Vomiting, Pharmaceutical industry

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada. The new study was derived from the Canadian Cannabis Patient Survey (CCPS) 2021, comprised of 2,697 patients and focused primarily on older patients with a mean age of 54.3. This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.

Key Points: 
  • Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use
    NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada .
  • This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.
  • The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients.
  • José Tempero, Tilray’s Medical Director, said, "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis."

European Parliament Recognizes Essential Tremor as Official Disease in Ground-Breaking Declaration

Retrieved on: 
Dienstag, April 9, 2024
European Parliament, Myenteric plexus, Movement disorder, Environment, Disease, Social justice, Patient, DSM-IV codes, Joint Declaration, Hope, Quality of life, Parliament, Essential tremor, European, Geography, Insightec, Pharmaceutical industry

BRUSSELS, April 9, 2024 /PRNewswire/ -- The European Parliament, in collaboration with Insightec and patient advocacy groups, has taken a historic step forward in the healthcare realm by signing a Joint Declaration to officially recognize essential tremor as a disease. This monumental move promises to enhance the lives of millions who suffer from the most common movement disorder worldwide, affecting an estimated 54 million people.

Key Points: 
  • The Joint Declaration specifically calls for the following:
    The formal recognition of essential tremor as a distinct disease.
  • "Access to treatment options for essential tremor is a matter of equality and social justice," echoes Maarit Matjussi, chair of ScanShakers and chairwoman of the Finnish Essential Tremor Association.
  • "Signing this Joint Declaration, together with Members of the European Parliament and patient associations across Europe, is a pivotal milestone for Insightec and for people living with essential tremor across Europe.
  • Members of the European Parliament, Insightec, and patient groups are united in their commitment to ensuring equal therapy access and improving quality of life for all affected by this disease.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Dienstag, März 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

People with Essential Tremor May Have Increased Risk of Dementia

Retrieved on: 
Mittwoch, März 6, 2024
Head, Master of Science, Bangladesh Technical Education Board, Social media, Nervous system, Alzheimer's disease, Arm, Physician, Thought, Stroke, Tremor, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Prevalence, Multiple sclerosis, Parkinson's disease, Human, University, Essential tremor, Movement disorder, Dementia, Eating, Concussion, Epilepsy, Diagnosis, Brain, Research, Jaw, American Academy, Pharmaceutical industry

Essential tremor is the most common tremor disorder, more common than Parkinson's disease.

Key Points: 
  • Essential tremor is the most common tremor disorder, more common than Parkinson's disease.
  • "Not only do tremors affect a person's ability to complete daily tasks such writing and eating, our study suggests that people with essential tremor also have an increased risk of developing dementia."
  • The study involved 222 people with essential tremor who had an average age of 79 at the start of the study.
  • "While the majority of people with essential tremor will not develop dementia, our findings provide the basis for physicians to educate people with essential tremor and their families about the heightened risk, and any potential life changes likely to accompany this diagnosis," Louis said.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Mittwoch, Februar 14, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, PD, Research, Sale, Tremor, Health care, NMDA, Innovation, Webcast, Plasma, Incidence, GABAA, CIV, Standard of care, Deficit spending, Therapy, European Medicines Agency, Food and Drug Administration, MCI, NEST, HCP, Woman, Schedule, USAN, Postpartum depression, ODD, Safety, Prescription, Insurance, EMA, FDA, Food, Passport, DEA, PAM, DSM-IV codes, Risk, PPD, Patient, MHRA, Cognition, Essential tremor, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

INSIGHTEC ANNOUNCES EXABLATE PRIME -THE NEXT GENERATION OF MR-GUIDED FOCUSED ULTRASOUND

Retrieved on: 
Montag, Januar 29, 2024
Intuition, Patient, SDR, Research, Temperature, Health, DSM-IV codes, Feedback, AC, Algorithm, Sale, Acquisition, Safety, Neurosurgery, Essential tremor

HAIFA, Israel and MIAMI, Jan. 29, 2024 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced its launch of Exablate Prime, a significant enhancement to the Exablate Neuro platform. Based on customer input and feedback, Exablate Prime is the culmination of over 10 years of significant research and development designed to increase precision, efficiency, and experience of the surgeon – and the patient.

Key Points: 
  • HAIFA, Israel and MIAMI, Jan. 29, 2024 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced its launch of Exablate Prime, a significant enhancement to the Exablate Neuro platform.
  • Like its predecessor, Exablate Prime enables incisionless neurosurgery as an outpatient procedure to provide relief to people living with movement disorders, such as essential tremor.
  • "Our unwavering commitment to enhancing patient care through innovative technology led us to develop Exablate Prime," said Maurice R. Ferre, M.D.
  • "Although Exablate Neuro has revolutionized the field of neurosurgery, Exablate Prime takes it to entirely new levels, pushing the boundaries of what is possible.

Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+

Retrieved on: 
Donnerstag, Januar 25, 2024
Patient, Research, DBS, DSM-IV codes, Communication, University, Parkinson's disease, PINS, Food, Deep brain stimulation, Travel, Movement, Neurosurgery, FDA, Wi-Fi, Boston Scientific, Essential tremor, Movement disorder, IOS, Use

"The Liberta RC DBS system excels in both areas, as a compact rechargeable device with the lowest recharge requirement of any FDA-approved DBS system.

Key Points: 
  • "The Liberta RC DBS system excels in both areas, as a compact rechargeable device with the lowest recharge requirement of any FDA-approved DBS system.
  • This achievement, coupled with the integration of remote programming capabilities, is a significant advancement for patients."
  • "In developing the Liberta RC DBS system, our focus has been on the unique experiences of individuals with chronic conditions like movement disorders," said Pedro Malha, vice president, neuromodulation, Abbott.
  • This system exemplifies our drive to providing patient-first solutions, combining effective therapy, effortless recharging, and remote programming capabilities."